DNB Markets – Isofol Medical: AGENT phase III trial fails
Isofol Medical announced that the phase III trial AGENT had failed to reach its primary and most important secondary endpoints. This is a huge disappointment and reduces the company’s valuation significantly (as arfolitixorin – the drug evaluated in the AGENT trial – was its only asset in clinical development). We have cut our fair value to SEK0–3 (14–26).AGENT phase III trial in mCRC failed to reach its endpoints. The AGENT trial compared mFOLFOX-6 + bevacizumab (Avastin) in mCRC patients, but arfolitixorin replaced leucovorin; the aim was to reach an increase in ORR of 〉10% (primary